CETUFTIRI, a new combination of UFT with leucovorin (LV), irinotecan, and cetuximab as first-line treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Preliminary results from a multicenter phase II trial

被引：0
|
作者：
Bennouna, J.
Faroux, R.
Francois, E.
Ligeza, C.
El Hannani, C.
Perrier, H.
Jacob, J.
Desseigne, F.
Perrocheau, G.
Douillard, J. Y.
机构：
[1] Ctr Rene Gauducheau, St Herblain, France
[2] Ctr Hosp La Roche Sur Yon, La Roche Sur Yon, France
[3] Ctr Antoine Lacassagne, Nice, France
[4] Ctr Etienne Dolet, St Nazaire, France
[5] Ctr Hosp Chateaubriand, Chateaubriand, France
[6] Hop St Joseph, Marseille, France
[7] Ctr Francois Baclesse, Caen, France
[8] Ctr Leon Berard, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4087
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Preliminary phase II study results of capecitabine (X) plus irinotecan (I) plus bevacizumab (A) as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC)
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
    E Vasile
    G Masi
    L Fornaro
    S Cupini
    F Loupakis
    S Bursi
    I Petrini
    S Di Donato
    I M Brunetti
    S Ricci
    A Antonuzzo
    S Chiara
    D Amoroso
    M Andreuccetti
    A Falcone
    British Journal of Cancer, 2009, 100 : 1720 - 1724
  • [23] Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial
    Souglakos, J
    Mavroudis, D
    Kakolyris, S
    Kourousis, C
    Vardakis, N
    Androulakis, N
    Agelaki, S
    Kalbakis, K
    Tsetis, D
    Athanasiadis, N
    Samonis, G
    Georgoulias, V
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) : 2651 - 2657
  • [24] First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer -: Mature results of a multicenter phase II study
    Aparicio, J
    Vicent, JM
    Maestu, I
    Bosch, C
    Galán, A
    Busquier, I
    Llorca, C
    Garcerá, S
    Campos, JM
    López-Tendero, P
    Balcells, M
    ONCOLOGY, 2005, 68 (01) : 58 - 63
  • [25] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST -LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Bounedjar, A.
    Smail, F.
    ANNALS OF ONCOLOGY, 2010, 21 : 67 - 68
  • [26] CAPECITABINE AND IRINOTECAN (CAPIRI) AS FIRST - LINE TREATMENT FOR PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Adda, B.
    Farida, S.
    ANNALS OF ONCOLOGY, 2009, 20 : 73 - 73
  • [27] Phase II trial of 5-fluorouracil (5FU)/leucovorin (LV), irinotecan, and oxaliplatin (FOLFOXIRI) plus cetuximab in patients with metastatic colorectal cancer (mCRC).
    Sougklakos, I.
    Vardakis, N. K.
    Kampouraki, E.
    Kotortsi, I.
    Androulakis, N. E. M.
    Vamvakas, L.
    Kalbakis, K.
    Hatzidaki, D.
    Mavroudis, D.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Phase I/II study of 24-hour infusion of irinotecan (CPT-11) in combination with sequential oral leucovorin (LV) and uracil/tegafur (UFT) for patients (PTS) with metastatic colorectal cancer (MCRC)
    Sadahiro, Sotaro
    Maeda, Yuji
    Suzuki, Toshiyuki
    Makuuchi, Hiroyasu
    Kamijo, Akemi
    Murayama, Chieko
    ANNALS OF ONCOLOGY, 2006, 17 : 117 - 117
  • [29] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Salvatore, L.
    Fornaro, L.
    Baldi, G.
    Stasi, I
    Cupini, S.
    Ciarlo, A.
    Del Monte, F.
    Trenta, P.
    Mezi, S.
    Rondini, M.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 12 - 12
  • [30] Capecitabine (X) plus weekly irinotecan (CAPIRI) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC): findings from a phase II trial of the Brazilian Oncology Consordium
    Barrios, Carlos Henrique
    Viola, Fabiana
    Coura, Luciana
    Del Giglio, Auro
    Malhias, Clarissa
    ANNALS OF ONCOLOGY, 2004, 15 : 89 - 90
12345